TSE:4151Pharmaceuticals
Kyowa Kirin (TSE:4151) Valuation Reconsidered After Amgen Ends Rocatinlimab Collaboration
Kyowa Kirin (TSE:4151) has moved back into the spotlight after Amgen ended their rocatinlimab collaboration. This decision leaves Kyowa Kirin to fully control the drug’s development, regulatory filings, and any future commercialization.
See our latest analysis for Kyowa Kirin.
The market reaction around the Amgen termination has been negative in the short term, with a 1-day share price return showing a 1.73% decline and a 7-day share price return showing an 11.95% decline. The 1-year total...